← Wave Life Sciences Ltd. (WVE) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Wave Life Sciences Ltd. (WVE)
Pharmaceutical Preparations · market cap $792M · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
4
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Wave Life Sciences (WVE) is a clinical-stage RNA medicine company with a four-asset Phase 2 pipeline spanning Alpha-1 Antitrypsin Deficiency (AATD), Duchenne Muscular Dystrophy (DMD), Huntington Disease (HD), and obesity. The company carries a $1.12B market cap, $544.6M in cash (roughly 27 months of runway), and a key Phase 2 data readout for lead asset WVE-006 in AATD expected around September 15, 2026.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| WVE-006 | Phase 2 | Alpha-1 Antitrypsin Deficiency |
| WVE-N531 | Phase 2 | Duchenne Muscular Dystrophy |
| SAD: 30mg WVE-003 | Phase 2 | Huntington Disease |
| WVE-007 | Phase 2 | Overweight and Obesity |
Price & technical context
3-month
-40.0%
6-month
-47.9%
12-month
-46.1%
52-wk range
$3.64–$21.31
vs 50-day MA
-23.7%
vs 200-day MA
-56.4%
Realized vol
130.5%
Max drawdown
-82.9%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for WVE (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.